Editorial Comment on “Efficacy of pembrolizumab plus lenvatinib as first‐line treatment for metastatic renal cell carcinoma with multiple brain metastases”
Saved in:
| Main Author: | Manabu Kato |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2025-01-01
|
| Series: | IJU Case Reports |
| Online Access: | https://doi.org/10.1002/iju5.12805 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Pembrolizumab Plus Lenvatinib for Metastatic Renal Cell Carcinoma in a Patient on Hemodialysis
by: Shimpei Yamashita, et al.
Published: (2025-05-01) -
Real-world outcomes of lenvatinib plus pembrolizumab in intermediate- and poor-risk metastatic renal cell carcinoma
by: Ilya Tsimafeyeu, et al.
Published: (2025-04-01) -
Pembrolizumab plus Lenvatinib in patients with metastatic Renal Cell Carcinoma: real-world evidences from the international ARON- 1 study
by: Camillo Porta, et al.
Published: (2025-05-01) -
Real world outcomes in patients with recurrent, advanced, or metastatic endometrial cancer treated with lenvatinib plus pembrolizumab
by: A. Pawsey, et al.
Published: (2025-05-01) -
Lenvatinib plus Pembrolizumab Combined with Transarterial Chemoembolization in Intermediate-Stage Hepatocellular Carcinoma
by: Masatoshi Kudo
Published: (2025-01-01)